Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 737.67 USD 2.09% Market Closed
Market Cap: 699.3B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one LLY stock under the Base Case scenario is 300.92 USD. Compared to the current market price of 737.67 USD, Eli Lilly and Co is Overvalued by 59%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LLY Relative Value
Base Case
300.92 USD
Overvaluation 59%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

14.3
P/S
P/S
Price to Sales
14.3
vs History
38
vs Industry
9
Median 3Y
15.6
Median 5Y
10.4
Industry
2.5
Forward
11.7
More Details
62.9
P/E
P/E
Price to Earnings
62.9
vs History
39
vs Industry
5
Median 3Y
69.1
Median 5Y
52.9
Industry
21.3
Forward
33.8
More Details
75
P/OCF
P/OCF
Price to OCF
75
vs History
33
vs Industry
5
Median 3Y
81.4
Median 5Y
40.7
Industry
16.7
More Details
63.6
P/FCFE
P/FCFE
Price to FCFE
63.6
vs History
44
vs Industry
5
Median 3Y
84.2
Median 5Y
54.6
Industry
24.7
More Details
44.3
P/B
P/B
Price to Book Value
44.3
vs History
36
vs Industry
0
Median 3Y
46.5
Median 5Y
35.3
Industry
2.1
More Details
14.9
EV/S
EV/S
Enterprise Value to Sales
14.9
vs History
38
vs Industry
8
Median 3Y
16.2
Median 5Y
10.8
Industry
2.6
Forward
12.2
More Details
18.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
18.2
vs History
39
vs Industry
9
Median 3Y
19.9
Median 5Y
14.2
Industry
5.1
More Details
33.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
33.9
vs History
47
vs Industry
7
Median 3Y
47.2
Median 5Y
31.3
Industry
12.8
Forward
28
More Details
37
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
37
vs History
52
vs Industry
8
Median 3Y
54.1
Median 5Y
36.7
Industry
16.3
Forward
30.3
More Details
78.4
EV/OCF
EV/OCF
Enterprise Value to OCF
78.4
vs History
33
vs Industry
5
Median 3Y
84.1
Median 5Y
42.1
Industry
14.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
0
Median 3Y
48.7
Median 5Y
44.5
Industry
18.2
More Details
8.8
EV/IC
EV/IC
Enterprise Value to IC
8.8
vs History
38
vs Industry
8
Median 3Y
9.6
Median 5Y
7.3
Industry
1.9
More Details

Multiples Across Competitors

LLY Competitors Multiples
Eli Lilly and Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eli Lilly and Co
NYSE:LLY
699.1B USD 14.3 62.9 33.9 37
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.4B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.6 19.2 13.3 15.3
CH
Roche Holding AG
SIX:ROG
211.2B CHF 3.5 25.5 9.6 11.2
CH
Novartis AG
SIX:NOVN
184.2B CHF 4.2 17.4 10.3 13.8
UK
AstraZeneca PLC
LSE:AZN
166.2B GBP 4.1 28.8 131 197.5
US
Merck & Co Inc
NYSE:MRK
193.3B USD 3 11.1 8.3 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
133.5B USD 2.1 16.9 7.3 10.3
FR
Sanofi SA
PAR:SAN
109.7B EUR 1.2 8.7 4.8 5.6
P/E Multiple
Earnings Growth PEG
US
Eli Lilly and Co
NYSE:LLY
Average P/E: 23.1
62.9
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.2
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.5
32%
0.8
CH
Novartis AG
SIX:NOVN
17.4
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.8
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.1
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.9
30%
0.6
FR
Sanofi SA
PAR:SAN
8.7
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBITDA: 394.4
33.9
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
13%
1
CH
Roche Holding AG
SIX:ROG
9.6
5%
1.9
CH
Novartis AG
SIX:NOVN
10.3
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.3
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.7
FR
Sanofi SA
PAR:SAN
4.8
7%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBIT: 1 697.7
37
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.3
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
CH
Novartis AG
SIX:NOVN
13.8
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.5
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.1
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1
FR
Sanofi SA
PAR:SAN
5.6
14%
0.4

See Also

Summary
LLY intrinsic value, competitors valuation, and company profile.
DCF Valuation
LLY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LLY stock valuation using valuation multiples.
Wall Street Estimates
LLY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LLY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 258,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.